Conatus Pharmaceuticals Inc. (CNAT)

[staccani]

The importance of High Portal Vein Pressure as main cause of LC decompensation. Emricasan has demonstrated is able to significantly reduce Severe Portal Vein Pressure hence reducing risk of decompensation. This is now object of the ongoing ph2b PH trial whose top line results are expected in 2018.
The two trials PH and forthcoming LF are basically addressing respectively the LC compensated patients (at high risk of developing decomensation) and the decompensated patients, with multiple dosages being tested, in order to confirm Emricasan safety and efficacy in treating basically the Cirrhotic patients who need it most.
Out of 50M plus patients suffering from Liver Cirrhosis globally due to all etiologies, there are globally at least 5M suffering from decompensated LC and probably 10M suffering from Severe Portal Pressure hence at high risk of developing decompensation. All of them would be potential Emricasan patients


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992331/